Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance [360p]

Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance [360p]

cancergrace

8 months
41 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.
Up Next Autoplay
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Category: General
2 Views
ash 3 days
Safety and Effectiveness of Apixaban #ASH19
Safety and Effectiveness of Apixaban #ASH19
Category: General
1 Views
ash 3 days
ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies
ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies
Category: General
1 Views
Cancer-News 5 days
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Category: General
4 Views
Mount Sinai Health System 1 month
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Category: General
26 Views
Cancer-News 2 months
Interesting Data Presented at WCLC 2019
Interesting Data Presented at WCLC 2019
Category: General
14 Views
Cancer-News 2 months
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Category: General
20 Views
Cancer-News 2 months
The iQ Group Global acquires new anticancer drug platform from University of Texas
The iQ Group Global acquires new anticancer drug platform from University of Texas
Category: General
13 Views
Cancer-News 2 months
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Category: General
119 Views
Annual-Meeting 6 months
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Category: General
27 Views
Annual-Meeting 6 months